Hiroyoshi M, Tateishi K, Yasunami Y, Maeshiro K, Ono J, Matsuoka Y, Ikeda S
Department of Surgery, School of Medicine, Fukuoka University, Japan.
Am J Gastroenterol. 1999 Apr;94(4):976-81. doi: 10.1111/j.1572-0241.1999.01043.x.
The purpose of the present study was to evaluate plasma glucagon-like peptide-1 (GLP-1) responses after oral glucose ingestion in patients with chronic pancreatitis and to clarify how GLP-1 secretion relates to pancreatic diabetes.
An oral glucose tolerance test (OGTT) was performed in 17 patients with chronic pancreatitis. Plasma glucose, immunoreactive insulin (IRI), C-peptide, glucagon, and GLP-1 levels at each time point during OGTT were measured. The diagnosis of chronic pancreatitis was made by the findings of endoscopic retrograde pancreatography (ERP): evident dilation of the main pancreatic duct with or without pancreatolithiasis.
The patients were divided into three groups according to the World Health Organization classification of diabetes based on plasma glucose levels after OGTT. The groups were: normal (three patients), impaired glucose tolerant (IGT) (six patients), and diabetic (DM) (eight patients). In the DM group, IRI and C-peptide response levels after oral glucose ingestion were significantly reduced as compared with those of the normal and IGT groups. No significant glucagon responses to oral glucose ingestion were found in the three groups. In contrast, plasma GLP-1 levels were significantly elevated after oral glucose ingestion in the DM groups as compared with normal and IGT groups.
The present study affords evidence that plasma GLP-1 levels become elevated with development of pancreatic diabetes, although the precise mechanism of this elevation remains undetermined.
本研究旨在评估慢性胰腺炎患者口服葡萄糖后血浆胰高血糖素样肽-1(GLP-1)的反应,并阐明GLP-1分泌与胰腺性糖尿病的关系。
对17例慢性胰腺炎患者进行口服葡萄糖耐量试验(OGTT)。测量OGTT期间各时间点的血浆葡萄糖、免疫反应性胰岛素(IRI)、C肽、胰高血糖素和GLP-1水平。慢性胰腺炎的诊断依据内镜逆行胰胆管造影(ERP)结果:主胰管明显扩张,伴或不伴有胰石症。
根据世界卫生组织基于OGTT后血浆葡萄糖水平的糖尿病分类,将患者分为三组。分组如下:正常(3例患者)、糖耐量受损(IGT)(6例患者)和糖尿病(DM)(8例患者)。在DM组中,口服葡萄糖后IRI和C肽反应水平与正常组和IGT组相比显著降低。三组中未发现口服葡萄糖后有明显的胰高血糖素反应。相比之下,与正常组和IGT组相比,DM组口服葡萄糖后血浆GLP-1水平显著升高。
本研究提供了证据,表明随着胰腺性糖尿病的发展,血浆GLP-1水平升高,尽管这种升高的确切机制尚不清楚。